Navigation Links
ATS Medical Announces Third Quarter 2009 Results
Date:11/2/2009

er, the Company announced that Columbia University Medical Center achieved a milestone 100 implants of the ATS 3f® Aortic Bioprosthesis. The Columbia University surgeons have utilized the ATS 3f® Aortic Bioprosthesis predominantly in small aortic roots where conventional stented tissue valves often involve a tradeoff in terms of clinical performance.
  • ATS sponsored a 3f Revolution Symposium at the EACTS meeting in Vienna that included a faculty of key opinion leaders in aortic valve surgery. Professor Sven Martens from JW Goethe University in Frankfurt, Germany presented his results with the ATS 3f® Enable(TM) valve demonstrating excellent pressure gradients and good outcomes. Professor Thierry Carrel from the University of Berne, in Berne Switzerland presented on his surgical approach in performing a biological Bentall procedure

    • Heart Valve Repair

    • Heart valve repair revenue in the third quarter of 2009 was $1.2 million, an increase of 29% compared to the third quarter of 2008.
    • The Company announced FDA approval and first implants of a new ATS Simulus semi-rigid band. The semi-rigid band expands the Company's annuloplasty repair product portfolio to meet broader clinical applications. The Company anticipates at least one additional repair product launch prior to the end of 2009.

    Surgical Ablation

    • Cryoablation revenues of $4.5 million in the third quarter of 2009 increased 12% over third quarter of 2008.
    • The third quarter saw the early stages of U.S. launch for the new ATS CryoMaze® 10-S Surgical Cryoablation Probe, which offers increased support throughout the length of the ablation segment. The increased rigidity of the probe addresses the preference of some surgeons to have a cryoablation probe with the feel of a more substantial surgical instrument. The ATS CryoMaze 10-S Probe has optimal shape retention while remaining distinct
      '/>"/>

    SOURCE ATS Medical, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
    3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    4. Globus Medical Raises $110 Million in Series E Financing Round
    5. Quark Pharmaceuticals Appoints New Chief Medical Officer
    6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
    7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
    8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
    9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
    10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
    11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/16/2009)... -- HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an online ... million in 12% per annum short term debt financing. ... initial drawdown of $500,000, with accrued interest and principal ... with accrued interest and principal repayable in one year ... cashflow positive for any calendar month prior to December ...
    (Date:12/16/2009)... 16 EuroPharma, Inc. signs exclusive ... use of super absorbency BCM-95® curcumin and ... The exclusive distribution territory for these ... store channel and professional channel, which includes ... BCM-95® is a highly absorbable curcumin. ...
    (Date:12/16/2009)... 16 RealMed has been ranked ... the 2009 Top 20 Best in ... report. RealMed is a dynamic revenue cycle ... processing between healthcare providers and all ... firm specializing in vendor performance measurement in ...
    Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 59658 1MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 59658 2MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 59658 3New FDA Study Seeks Feedback on Lasik Surgery 59656 1New FDA Study Seeks Feedback on Lasik Surgery 59656 2Scientists Provide First Map of Complete Human Epigenome 59653 1Scientists Provide First Map of Complete Human Epigenome 59653 2
    ... Germany, June 5, 2007 – This,year’s American ... sees a wealth of promising new data ... further demonstrating the consistent efficacy and,versatility of ... of metastatic colorectal cancer (mCRC) and squamous ...
    ... Second Multinational Phase III Study Provides Further ... Inhibition in the Treatment,of Rheumatoid Arthritis, BASEL, ... (1), the second multinational phase III Actemra,(tocilizumab) ... that a greater proportion of patients treated ...
    Other Medicine Technology:Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 2Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 4Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 5Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 6Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 7Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 8New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4
    (Date:12/16/2009)... New Enterprise Associates, Inc. (NEA), a ... one of its portfolio companies, Acclarent, Inc., has ... by Ethicon, Inc., a Johnson & Johnson company, ... (net of estimated cash on hand at time ... designing, developing and commercializing devices that address conditions ...
    (Date:12/16/2009)... minorities might not gain full benefit from breakthroughs, experts ... embryonic stem cell lines currently used for research come ... , That could mean that non-whites will benefit less ... down the line, experts say. , Blacks could be ... used stem cell lines studied showed any traces of ...
    (Date:12/16/2009)... has never felt so good for "The Biggest Loser" ... means continuing to make smart choices everyday to help ... healthy choice that is an important part of living ... Every glass of milk has nine essential nutrients like ... blood pressure, and calcium and vitamin D for strong ...
    (Date:12/16/2009)... Dec. 16 For wounded U.S. ... Center in Washington, D.C., the holidays can be a ... to travel home rely more than ever on the ... This week, calling home just got easier for Walter ... calling cards, which will provide hundreds of minutes of ...
    (Date:12/16/2009)... As a result of C3: Colorectal Cancer ... reviewed cancer research program is included in the final ... new cancer research program will research cancers, like colorectal ... lung and ovarian cancer research programs run by the ... ,, The $15 million in funding for this new ...
    Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Most Stem Cells Used in Research Come From Whites 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3
    ... to assist in healing, MEMPHIS, Tenn. and ... (NYSE: SNN , LSE: SN) Orthopaedic Trauma ... of the CAPTION(TM),Disposable Platelet Concentration System. The CAPTION ... concentrate (PRC) and eliminates,cross- contamination risks., The ...
    ... ATLANTA, March 5 ADAMS Management Services Corporation,(ADAMS), ... services,for the healthcare industry, announces the addition of ... the firm,s staff. Ms. Aiken and Mr.,Cannaday have ... Program,Management division of the firm, and are both ...
    ... Since 1999,OurHealthNetwork.com ( http://www.OurHealthNetwork.com ) has been the,Internet,s ... of board- certified podiatrists now introduces an exclusive ... custom orthotics that not only,provide relief to those ... to their,lifestyles and shoe styles. Now for the ...
    ... JOLLA, Calif., March 5 DermTech, a biotechnology,company ... and other diseases, today announced that Allan C. ... Halpern is Chief of,Dermatology at Memorial Sloan-Kettering Cancer ... early detection and management of melanoma in high-risk,individuals., ...
    ... Air Methods Corporation,(Nasdaq: AIRM ) will report financial ... the close of the market on Wednesday, March 12,2008. ... March 12,2008 at 4:15 p.m. Eastern to discuss these ... dialing (888) 396-5640,(domestic) or (706) 643-0580 (international) or by ...
    ... G-Protein Coupled Receptors, BERWYN, Penn., March 5 ... developing pharmaceutical products targeting G-protein,coupled receptors (GPCRs), today ... financing. Alta Partners and Healthcare Ventures led the ... New Enterprise Associates and,Polaris Venture Partners. The company ...
    Other Medicine News:Health News:Smith & Nephew Introduces New Biologic to Speed Healing 2Health News:Smith & Nephew Introduces New Biologic to Speed Healing 3Health News:ADAMS Welcomes Debbie Aiken and Brandon Cannaday to the Firm's Staff as Associate Project Managers 2Health News:ADAMS Welcomes Debbie Aiken and Brandon Cannaday to the Firm's Staff as Associate Project Managers 3Health News:Unique Line of Custom-Made Orthotics for Sandals and Clogs Cater to Style-Minded Foot Pain Sufferers 2Health News:DermTech Adds Allan C. Halpern, MD, Chief of Dermatology at Memorial Sloan- Kettering Cancer Center, to Company's Melanoma Advisory Board 2Health News:Trevena, Inc. Announces $24 Million Series A Financing 2Health News:Trevena, Inc. Announces $24 Million Series A Financing 3
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: